|
Apr 29
|
Pfizer offers 'longer-term' opportunity amid tariff uncertainty
|
|
Apr 29
|
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
|
|
Apr 29
|
Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug
|
|
Apr 28
|
Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting
|
|
Apr 28
|
Temu, Tesla prices, Merck KGaA deal: Trending Tickers
|
|
Apr 27
|
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
|
|
Apr 27
|
Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks
|
|
Apr 26
|
Akeso survival data for ivonescimab misses expectations, STAT says
|
|
Apr 10
|
Merck (NYSE:MRK) Faces Multiple Shareholder Proposals Ahead Of Annual Meeting
|
|
Apr 10
|
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
|
|
Apr 9
|
Apple, Alibaba, drugmaker stocks: Trending Tickers
|
|
Apr 9
|
Trump says pharmaceutical tariffs may be coming: What to know
|
|
Apr 9
|
Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan
|
|
Apr 9
|
Trump Tariff News: New Tariffs Begin, China Retaliates; Treasury Yields Spike While Delta, Walmart Pull Guidance
|
|
Feb 18
|
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
|
|
Feb 11
|
Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant trea...
|